© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Abivax S.A. (ABVX) stock surged +0.06%, trading at $121.55 on NASDAQ, up from the previous close of $121.48. The stock opened at $121.69, fluctuating between $119.51 and $121.99 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 14, 2026 | 122.17 | 127.44 | 121.03 | 125.80 | 934.57K |
| Apr 13, 2026 | 122.00 | 126.00 | 120.19 | 121.31 | 1.51M |
| Apr 10, 2026 | 126.00 | 128.42 | 122.55 | 126.14 | 997.84K |
| Apr 09, 2026 | 119.96 | 126.00 | 119.84 | 125.69 | 1.06M |
| Apr 08, 2026 | 120.30 | 120.75 | 117.00 | 118.96 | 437.15K |
| Apr 07, 2026 | 119.06 | 119.06 | 113.75 | 116.48 | 389.06K |
| Apr 06, 2026 | 117.89 | 120.00 | 117.00 | 119.47 | 297.06K |
| Apr 02, 2026 | 112.00 | 119.79 | 112.00 | 118.37 | 954.74K |
| Apr 01, 2026 | 113.21 | 118.80 | 113.21 | 114.97 | 1.08M |
| Mar 31, 2026 | 102.39 | 112.91 | 102.39 | 111.35 | 1.3M |
| Mar 30, 2026 | 103.50 | 104.80 | 100.15 | 101.50 | 752.54K |
| Mar 27, 2026 | 108.24 | 108.43 | 102.00 | 102.47 | 1.75M |
| Mar 25, 2026 | 112.00 | 113.75 | 110.13 | 110.70 | 781.82K |
| Mar 24, 2026 | 116.16 | 116.92 | 109.08 | 110.17 | 1.36M |
| Mar 23, 2026 | 120.63 | 123.00 | 115.01 | 115.42 | 1.28M |
| Mar 20, 2026 | 123.99 | 126.86 | 120.01 | 120.34 | 1.32M |
| Mar 19, 2026 | 122.50 | 124.99 | 120.47 | 123.03 | 734.76K |
| Mar 18, 2026 | 126.01 | 126.01 | 122.26 | 123.99 | 700.09K |
| Mar 17, 2026 | 123.51 | 127.00 | 123.32 | 126.62 | 690.79K |
| Mar 16, 2026 | 119.99 | 123.72 | 118.55 | 122.75 | 1.59M |
ABIVAX Soci�t� Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Soci�t� Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
| Employees | 69 |
| Beta | -0.1 |
| Sales or Revenue | $4.62M |
| 5Y Sales Change% | 0.34% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |